drugset / Trial / NCT06509971
A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
* Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. * Secondary Purpose To evaluate the safety of QL1706 in combination with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. Exploratory analysis of the association between the efficacy of the combination regimen and biomarkers.
Timeline
- Start
- 2024-07
- Primary completion
- 2026-02
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
Indications
No indication recorded.